Isomorphic Labs unveils IsoDDE drug-discovery engine, hailed as ‘an AlphaFold 4’
But proprietary
Event confirmedAwaiting review
Status
- Claim
Event confirmedAwaiting review
- Our reporting
- High confidence
- Verification
- Preprint only
- Importance
- 3 of 5
- Last verified
- 29 September 2026
Your AI and this story
- GPT-6 AstraIn its training data
- Claude Opus 5.5In its training data
- Gemini 4 HydrogenIn its training data
- Grok 4.7In its training data
It happened before the cutoffs of all four assistants, so it can be in their training data.
Key facts
- Announced 2026-02-10 via a 27-page technical report; model not released
- Beats Boltz-2 and physics-based methods at binding-affinity prediction; state of the art on antibody–target interactions; generalises to molecules unlike its training data
- Mohammed AlQuraishi: ‘a major advance, on the scale of an AlphaFold4... The problem is that we know nothing of the details.’
What happened
Isomorphic Labs, led by Demis Hassabis, described IsoDDE, a successor-class system to AlphaFold 3 aimed at drug discovery, in a technical report without releasing code or weights.
Why it matters
Shows AI structural biology continuing to advance fast, but also a shift from DeepMind’s open-science AlphaFold tradition toward proprietary commercial models.
What is disputed or not yet verified
| Verification | Company technical report only; not peer-reviewed, model not released |
|---|
Sources
2 sources from 2 sites. Numbers match the chips in the text.
2 sources: 2 press
Press
- Nature: ‘An AlphaFold 4’ — scientists marvel at DeepMind drug spin-off’s exclusive new AInature.com, press
- Scientific American (reprint of Nature news)scientificamerican.com, press
Changes
- See Isomorphic Labs raises $2.1B Series B for the $2.1B Series B and the slipped clinical-trial timeline
- Added science block (science & math tab)
- Filed